The WWP1 ubiquitin E3 ligase increases TRAIL resistance in breast cancer

International Journal of Cancer

Volumn 130, Issue 7, 2012, Pages 1504-1510

  Zhou, Zhongmei ^a,b   Liu, Rong ^b   Chen, Ceshi ^a,b  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

apoptosis; breast cancer; caspase 8; TRAIL; WWP1

Indexed keywords

CASPASE 8; DEATH RECEPTOR; ESTROGEN RECEPTOR ALPHA; FLICE INHIBITORY PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DEPLETION; STABLE EXPRESSION; TUMOR GENE; UPREGULATION; WW DOMAIN CONTAINING E3 UBIQUITIN PROTEIN LIGASE 1 GENE;

APOPTOSIS; BREAST NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MUTATION; RECEPTORS, DEATH DOMAIN; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES;

EID: 84856350008     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26122     Document Type: Article

References (29)

1. Chen C, Sun X, Guo P, Dong XY, Sethi P, Zhou W, Zhou Z, Petros J, Frierson HF, Jr, Vessella RL, Atfi A, Dong JT,. Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 2007; 26: 2386-94. (Pubitemid 46572813)
2. Chen C, Zhou Z, Ross JS, Zhou W, Dong JT,. The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer 2007; 121: 2834-41.
3. Nguyen Huu NS, Ryder WD, Zeps N, Flasza M, Chiu M, Hanby AM, Poulsom R, Clarke RB, Baron M,. Tumour-promoting activity of altered WWP1 expression in breast cancer and its utility as a prognostic indicator. J Pathol 2008; 216: 93-102.
4. Chen C, Zhou Z, Sheehan CE, Slodkowska E, Sheehan CB, Boguniewicz A, Ross JS,. Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma. Int J Cancer 2009; 124: 2829-36.
5. Chen C, Zhou Z, Liu R, Li Y, Azmi PB, Seth AK,. The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11. Oncogene 2008; 27: 6845-55.
6. Seo SR, Lallemand F, Ferrand N, Pessah M, L'Hoste S, Camonis J, Atfi A,. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J 2004; 23: 3780-92. (Pubitemid 39389709)
7. Li Y, Zhou Z, Chen C,. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 2008; 15: 1941-51.
8. Li Y, Zhou Z, Alimandi M, Chen C,. WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer. Oncogene 2009; 28: 2948-58.
9. Feng SM, Muraoka-Cook RS, Hunter D, Sandahl MA, Caskey LS, Miyazawa K, Atfi A, Earp HS, III,. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation. Mol Cell Biol 2009; 29: 892-906.
10. Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, Miyazono K, Miyazawa K,. Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene 2004; 23: 6914-23. (Pubitemid 39279992)
11. Moren A, Imamura T, Miyazono K, Heldin CH, Moustakas A,. Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J Biol Chem 2005; 280: 22115-23. (Pubitemid 40827867)
12. Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X, Zhou J, Ling J, Simons JW, Lingrel JB, Dong JT,. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 2005; 280: 41553-61. (Pubitemid 41832217)
13. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A,. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-90. (Pubitemid 26175834)
14. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S,. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 2009; 113: 217-30.
15. Boldin MP, Goncharov TM, Goltsev YV, Wallach D,. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85: 803-15.
16. Chang DW, Xing Z, Capacio VL, Peter ME, Yang X,. Interdimer processing mechanism of procaspase-8 activation. EMBO J 2003; 22: 4132-42. (Pubitemid 37021742)
17. Kurokawa M, Kornbluth S,. Caspases and kinases in a death grip. Cell 2009; 138: 838-54.
18. Li H, Zhu H, Xu CJ, Yuan J,. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501. (Pubitemid 28391865)
19. Kagawa S, Gu J, Honda T, McDonnell TJ, Swisher SG, Roth JA, Fang B,. Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death. Clin Cancer Res 2001; 7: 1474-80. (Pubitemid 32708705)
20. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H,. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599-609.
21. Herr I, Wilhelm D, Meyer E, Jeremias I, Angel P, Debatin KM,. JNK/SAPK activity contributes to TRAIL-induced apoptosis. Cell Death Differ 1999; 6: 130-5. (Pubitemid 29082301)
22. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M,. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006; 124: 601-13. (Pubitemid 43199444)
23. Panner A, Crane CA, Weng C, Feletti A, Parsa AT, Pieper RO,. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res 2009; 69: 7911-16.
24. Yang F, Tay KH, Dong L, Thorne RF, Jiang CC, Yang E, Tseng HY, Liu H, Christopherson R, Hersey P, Zhang XD,. Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death Differ 2010; 17: 1354-67.
25. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK,. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003; 63: 5390-400. (Pubitemid 37139856)
26. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S,. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734-41. (Pubitemid 29076075)
27. Krueger A, Baumann S, Krammer PH, Kirchhoff S,. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001; 21: 8247-54. (Pubitemid 33108586)
28. Dolcet X, Llobet D, Pallares J, Rue M, Comella JX, Matias-Guiu X,. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 2005; 85: 885-94. (Pubitemid 41021297)
29. Day TW, Huang S, Safa AR,. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol 2008; 76: 1694-704.